We are analyzing https://link.springer.com/article/10.1007/s40264-018-0779-3.

Title:
Safety and Tolerability of Adoptive Cell Therapy in Cancer | Drug Safety
Description:
Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection. In recent years, some ACTs have produced unprecedented breakthrough responses: TIL therapy has moved from melanoma to solid tumor applications, TCR-engineered cells are developed for hematologic and solid tumors, and CAR-engineered T cells have received Food and Drug Administration (FDA) approval for the treatment of patients with certain B-cell malignancies. Although results are encouraging, to date, only a small percentage of patients with advanced malignancies can benefit from ACT. Besides ACT availability and accessibility, treatment-related toxicities represent a major hurdle in the widespread implementation of this therapeutic modality. The large variety of observed toxicities is caused by the infused cell product or as side effects of accompanying medication and chemotherapy. Toxicities can occur immediately or can be delayed. In order to render those highly promising therapeutic approaches safe enough for a wider pool of patients outside of clinical trials, an international consensus for toxicity management needs to be established.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

pubmed, article, google, scholar, cas, central, cancer, cell, cells, therapy, patients, lymphocytes, adoptive, clin, tcell, melanoma, receptor, antigen, med, metastatic, transfer, res, oncol, tumor, chimeric, nat, dudley, gene, immunotherapy, human, sci, yang, tumorinfiltrating, interleukin, toxicity, safety, management, rosenberg, van, httpsdoiorgccr, immunol, httpsdoiorgs, blood, httpsdoiorgblood, engineered, treatment, receptors, httpsdoiorgjco, arber, car,

Topics {✒️}

anti-cd19 chimeric-antigen-receptor-transduced titin-derived hla-a1-presented peptide lethal graft-versus-host disease ebv-specific t-cell infusions t-cell-receptor gene therapy month download article/chapter human papillomavirus-targeted tumor-infiltrating chimeric antigen receptor-modified suicide-gene-engineered donor lymphocytes ny-eso-1-specific tcr-engineered allogeneic graft-versus-leukemia t-cell receptor [tcr] transduced tumor-specific tcrs tumor-infiltrating lymphocyte cultures safer t-cell therapy engineered mage a3-directed lionel trueb & george coukos autologous tumor antigen-specific antigen-negative humanized mice human t-cell receptors dr benita wolf transposon-based gene therapy cell receptor complex engineered t-cell therapies prolonged disease-free period car t-cell therapy tumor-infiltrating lymphocytes [til] autologous tumor-infiltrating lymphocytes indolent b-cell malignancies anti-lymphoma/leukemia effects chimeric antigen receptor cd19-targeted therapy ctl019 adoptive t-cell transfer dr melita irving t-cell transfer immunotherapy hsv-tk gene transfer author correspondence lentivirus-mediated gene transfer low-dose recombinant interleukin-2 full article pdf cognate peptide presented cell-mediated tumor immunotherapy article wolf t-cell therapy dual hla class chimeric antigen receptors t-cell receptors dr lionel trueb blood-brain barrier disruption tumor-infiltrating lymphocytes

Questions {❓}

Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?
T-cell receptor gene therapy—ready to go viral?
TCR-engineered T cells to treat tumors: seeing but not touching?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Safety and Tolerability of Adoptive Cell Therapy in Cancer
         description:Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection. In recent years, some ACTs have produced unprecedented breakthrough responses: TIL therapy has moved from melanoma to solid tumor applications, TCR-engineered cells are developed for hematologic and solid tumors, and CAR-engineered T cells have received Food and Drug Administration (FDA) approval for the treatment of patients with certain B-cell malignancies. Although results are encouraging, to date, only a small percentage of patients with advanced malignancies can benefit from ACT. Besides ACT availability and accessibility, treatment-related toxicities represent a major hurdle in the widespread implementation of this therapeutic modality. The large variety of observed toxicities is caused by the infused cell product or as side effects of accompanying medication and chemotherapy. Toxicities can occur immediately or can be delayed. In order to render those highly promising therapeutic approaches safe enough for a wider pool of patients outside of clinical trials, an international consensus for toxicity management needs to be established.
         datePublished:2019-01-16T00:00:00Z
         dateModified:2019-01-16T00:00:00Z
         pageStart:315
         pageEnd:334
         sameAs:https://doi.org/10.1007/s40264-018-0779-3
         keywords:
            Drug Safety and Pharmacovigilance
            Pharmacology/Toxicology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40264-018-0779-3/MediaObjects/40264_2018_779_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40264-018-0779-3/MediaObjects/40264_2018_779_Fig2_HTML.png
         isPartOf:
            name:Drug Safety
            issn:
               1179-1942
               0114-5916
            volumeNumber:42
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Benita Wolf
               affiliation:
                     name:University of Lausanne
                     address:
                        name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stefan Zimmermann
               url:http://orcid.org/0000-0002-3562-0918
               affiliation:
                     name:University of Lausanne
                     address:
                        name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Caroline Arber
               affiliation:
                     name:University of Lausanne
                     address:
                        name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Melita Irving
               affiliation:
                     name:University of Lausanne
                     address:
                        name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lionel Trueb
               affiliation:
                     name:University of Lausanne
                     address:
                        name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:George Coukos
               affiliation:
                     name:University of Lausanne
                     address:
                        name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Safety and Tolerability of Adoptive Cell Therapy in Cancer
      description:Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection. In recent years, some ACTs have produced unprecedented breakthrough responses: TIL therapy has moved from melanoma to solid tumor applications, TCR-engineered cells are developed for hematologic and solid tumors, and CAR-engineered T cells have received Food and Drug Administration (FDA) approval for the treatment of patients with certain B-cell malignancies. Although results are encouraging, to date, only a small percentage of patients with advanced malignancies can benefit from ACT. Besides ACT availability and accessibility, treatment-related toxicities represent a major hurdle in the widespread implementation of this therapeutic modality. The large variety of observed toxicities is caused by the infused cell product or as side effects of accompanying medication and chemotherapy. Toxicities can occur immediately or can be delayed. In order to render those highly promising therapeutic approaches safe enough for a wider pool of patients outside of clinical trials, an international consensus for toxicity management needs to be established.
      datePublished:2019-01-16T00:00:00Z
      dateModified:2019-01-16T00:00:00Z
      pageStart:315
      pageEnd:334
      sameAs:https://doi.org/10.1007/s40264-018-0779-3
      keywords:
         Drug Safety and Pharmacovigilance
         Pharmacology/Toxicology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40264-018-0779-3/MediaObjects/40264_2018_779_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40264-018-0779-3/MediaObjects/40264_2018_779_Fig2_HTML.png
      isPartOf:
         name:Drug Safety
         issn:
            1179-1942
            0114-5916
         volumeNumber:42
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Benita Wolf
            affiliation:
                  name:University of Lausanne
                  address:
                     name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stefan Zimmermann
            url:http://orcid.org/0000-0002-3562-0918
            affiliation:
                  name:University of Lausanne
                  address:
                     name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Caroline Arber
            affiliation:
                  name:University of Lausanne
                  address:
                     name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Melita Irving
            affiliation:
                  name:University of Lausanne
                  address:
                     name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lionel Trueb
            affiliation:
                  name:University of Lausanne
                  address:
                     name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:George Coukos
            affiliation:
                  name:University of Lausanne
                  address:
                     name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Drug Safety
      issn:
         1179-1942
         0114-5916
      volumeNumber:42
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Lausanne
      address:
         name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
         type:PostalAddress
      name:University of Lausanne
      address:
         name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
         type:PostalAddress
      name:University of Lausanne
      address:
         name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
         type:PostalAddress
      name:University of Lausanne
      address:
         name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
         type:PostalAddress
      name:University of Lausanne
      address:
         name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
         type:PostalAddress
      name:University of Lausanne
      address:
         name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Benita Wolf
      affiliation:
            name:University of Lausanne
            address:
               name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
               type:PostalAddress
            type:Organization
      name:Stefan Zimmermann
      url:http://orcid.org/0000-0002-3562-0918
      affiliation:
            name:University of Lausanne
            address:
               name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
               type:PostalAddress
            type:Organization
      name:Caroline Arber
      affiliation:
            name:University of Lausanne
            address:
               name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
               type:PostalAddress
            type:Organization
      name:Melita Irving
      affiliation:
            name:University of Lausanne
            address:
               name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
               type:PostalAddress
            type:Organization
      name:Lionel Trueb
      affiliation:
            name:University of Lausanne
            address:
               name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
               type:PostalAddress
            type:Organization
      name:George Coukos
      affiliation:
            name:University of Lausanne
            address:
               name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
      name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
      name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
      name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
      name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
      name:Department of Oncology, Lausanne University Hospital, and Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(558)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.68s.

LINK . SPRINGER . COM {}